MRUS

Merus N.V.

48.82 USD
-0.12 (-0.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Merus N.V. stock is up 37.83% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 February’s closed higher than January. In the last 7 Unusual Options Trades, there were 2 CALLs, 5 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 Jan 20:29 16 Feb, 2024 35.00 CALL 238 640
10 Jan 20:29 16 Feb, 2024 35.00 CALL 98 640
11 Jan 19:38 20 Dec, 2024 30.00 PUT 141 0
16 Jan 16:18 20 Dec, 2024 35.00 PUT 56 0
16 Jan 18:49 20 Dec, 2024 35.00 PUT 75 0
01 Feb 19:54 15 Mar, 2024 35.00 PUT 94 0
21 Feb 19:44 15 Mar, 2024 45.00 PUT 50 0

About Merus N.V.

Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.